Sign In
Buy WVE
$5.95
-0.300 (-4.80%)
At Close: Jul 13, 2026
CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of R
Does Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect?
10:55am, Wednesday, 01'st Jul 2026
The consensus price target hints at a 294.7% upside potential for Wave Life Sciences (WVE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earning
In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing
Wave Life Sciences (WVE) Upgraded to Buy: Here's Why
01:02pm, Tuesday, 16'th Jun 2026
Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wave Life Sciences Ltd. (WVE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
10:58am, Monday, 08'th Jun 2026
Wave Life Sciences Ltd. (WVE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Wave Life Sciences to Present at Upcoming Investor Conferences
08:30am, Monday, 01'st Jun 2026
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter
03:56pm, Sunday, 31'st May 2026
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform.
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Wave Life Sciences Ltd. (NASDAQ: WVE) or certain of its executive officers violated federal securities laws. T
Wave Life Sciences: 'Strong Buy' On DMD NDA Filing WVE-N531 And Released AATD Data
01:21pm, Wednesday, 20'th May 2026
Wave Life Sciences Ltd. retains a Strong Buy rating, driven by near-term Accelerated Approval catalysts for WVE-N531 and WVE-006. The company is on track to file an NDA for WVE-N531 in DMD exon 53 ski
Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1
09:49am, Tuesday, 19'th May 2026
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease. DURHAM, N.C.
Wave Life Sciences Ltd. (WVE) Shareholder/Analyst Call Transcript
01:50am, Tuesday, 19'th May 2026
Wave Life Sciences Ltd. (WVE) Shareholder/Analyst Call Transcript
Data reinforce WVE-006's potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with mo
Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference
04:05pm, Wednesday, 13'th May 2026
CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Pre-Market Stock Futures: Futures are trading modestly higher as we hit the midweek mark, and some buyers' exhaustion likely played a role, as all the major indices finished lower on Tuesday. This com
Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates
09:46am, Tuesday, 28'th Apr 2026
Wave Life Sciences (WVE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.29 per share a year ago.
